Find Locations
For hours, walk-ins and appointments.Synonyms
- GlycoMark®, 1-5 Anhydroglucitol
Expected Turnaround Time
3 - 5 days
Turnaround time is defined as the usual number of days from the date of pickup of a specimen for testing to when the result is released to the ordering provider. In some cases, additional time should be allowed for additional confirmatory or additional reflex tests. Testing schedules may vary.
Related Documents
Specimen Requirements
Specimen
Serum or plasma
Volume
1 mL
Minimum Volume
0.75 mL (Note: This volume does not allow for repeat testing.)
Container
Red-top tube, gel-barrier tube, or lavender-top (EDTA) tube
Collection
Separate serum or plasma from cells within one hour of collection.
Storage Instructions
Room temperature
Stability Requirements
Temperature | Period |
|---|---|
Room temperature | 7 days |
Refrigerated | 14 days |
Frozen | 14 days |
Freeze/thaw cycle | Stable x6 |
Test Details
Use
GlycoMark® testing provides an estimate of the patient's postmeal glucose over a one- to two-week period, making it ideal for intermediate term monitoring of glycemic control in diabetic patients. GlycoMark® testing can also help monitor the effectiveness of therapeutics targeting postprandial glucose (PPG)1,2 and is a useful adjunct to routine A1c testing, because it responds more rapidly and sensitively to hyperglycemia than A1c.1,2
Limitations
Individuals using INVOKANA® may demonstrate low levels of 1,5-AG. 1,5-AG blood levels are falsely lowered by the diabetes drug INVOKANA®, which prevents reabsorption of 1,5-AG in the kidneys. INVOKANA® belongs to new class of diabetes medication known as sodium-glucose cotransporter 2 (SGLT2) inhibitors, which block reabsorption of glucose in the kidneys, and other SGLT2 inhibitors may have the same effect. INVOKANA® is a trademark of Janssen Pharmaceuticals Inc.
Persistently positive urinary glucose levels, or oxyhyperglycemia after gastrectomy, may result in a low 1,5-AG value. Low values have also been observed in pregnancy, terminal stage renal failure, dialysis patients, advanced cirrhosis, and prolonged incapability of oral ingestion of food. Abnormal values have also been noted in individuals with abnormal glomerular filtration rates.3,4
For some patients with severe hyperglycemia, the internal pool of 1,5-AG may tend to remain depleted as a result of persistent glucosuria. In these cases, measurements of 1,5-AG may be less indicative of initial recovery following initiation of antidiabetic treatment.
1,5-AG values may be increased when some Chinese medicines, such as Polygala tenuifolia and senega syrup, are administered. Values may also be increased during intravenous hyperalimentation. 1,5-AG values may be lower in patients undergoing therapy with steroids.5
Some α-glucosidase inhibitors, such as acarbose, may potentially reduce 1,5-AG levels due to interference with intestinal absorption of 1,5-AG.
As with all diagnostic tests, GlycoMark® results should be interpreted along with clinical findings and results from other diagnostic methods.
Methodology
Enzymatic, colorimetric assay. GlycoMark® is a registered trademark of GlycoMark Inc, New York, NY.
Reference Interval
• <18 years: Not established
• Adult male: 10.7−32.0 μg/mL
• Adult female: 6.8−29.3 μg/mL
• Glycemic control goal for diabetic patients: >10
Additional Information
1,5 Anhydroglucitol (1,5-AG) is a naturally occurring monosaccharide found in nearly all foods. Individuals without diabetes and those with diabetes but have well-controlled blood glucose levels <180 mg/dL have detectably high levels of 1,5-AG. When an individual's glucose levels are in a normal range, 1,5-AG is naturally processed by the kidneys and nearly all of it is reabsorbed back into the blood stream by the renal proximal tubules. Individuals with diabetes who have blood glucose level excursion in excess >180 mg/dL can be expected to have low levels of 1,5-AG. In these individuals, excess glucose in the body is reabsorbed first by the kidneys, blocking 1,5-AG reabsorption. The body is unable to maintain a high steady state level of 1,5-AG in blood and tissues.
• Normal or high GlycoMark® values = Normal blood glucose levels
• Low GlycoMark® values = Elevated blood glucose levels or high blood glucose spikes
Footnotes
1. Dungan KM, Buse JB, Largay J, et al. 1,5-Anhydroglucitol and postprandial hyperglycemia as measured by continuous glucose monitoring system in moderately controlled patients with diabetes. Diabetes Care. 2006 Jun; 29(6):1214-1219. 16731998
2. Dworacka M, Winiarska H, Szymanska M, et al. 1,5-Anhydro-D-glucitol: A novel marker of glucose excursions. Int J Clin Pract Suppl. 2002 Jul; (129):40-44. 12166605
3.Yamanuchi S. Guide for Laboratory Tests. 1992: 597-599.
4. Minoda S. Influence of long-term total nutrition on l,5-anhydroglucitol in the human body.Teikyo Medical J. 1993; 6(4):321-333.
5. Kato C, Morishita Y, Fukatsu T. [False-positive increase in 1,5-anhydro-D-glucitol due to Kampo (Japanese herbal) medicine.] Rinsho Byori. 1996 Apr; 44(4):396-399. (Article in Japanese) 8847825
LOINC® Map
| Order Code | Order Code Name | Order Loinc | Result Code | Result Code Name | UofM | Result LOINC |
|---|---|---|---|---|---|---|
| 500115 | GlycoMark(R)(1,5 AG) | 53835-5 | 500117 | GlycoMark(R)(1,5 AG) | ug/mL | 53835-5 |
© 2021 Laboratory Corporation of America® Holdings and Lexi-Comp Inc. All Rights Reserved.
CPT Statement/Profile Statement
The LOINC® codes are copyright © 1994-2021, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee. Permission is granted in perpetuity, without payment of license fees or royalties, to use, copy, or distribute the LOINC® codes for any commercial or non-commercial purpose, subject to the terms under the license agreement found at https://loinc.org/license/. Additional information regarding LOINC® codes can be found at LOINC.org, including the LOINC Manual, which can be downloaded at LOINC.org/downloads/files/LOINCManual.pdf